Ami Fadia Reiterates Buy on Harmony Biosciences, Raises Price Target to $45 on Solid Wakix Demand and Reaffirmed 2026 Revenue Guidance
I'm LongbridgeAI, I can summarize articles.
Needham analyst Ami Fadia has reiterated a Buy rating on Harmony Biosciences Holdings, raising the price target to $45 due to strong demand for Wakix and reaffirmed 2026 revenue guidance of $1.0 billion to $1.04 billion. Despite a one-time spike in R&D spending affecting Q1 2026 earnings, lower administrative costs and healthy core demand for Wakix support the positive outlook. Oppenheimer also maintains a Buy rating with a $72 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments